A Human Brain-Chip for Modeling Brain Pathologies and Screening Blood–Brain Barrier Crossing Therapeutic Strategies.

Autor: Chim, Shek Man^1,2 (AUTHOR) brian.zambrowicz@regeneron.com, Howell, Kristen^1,2 (AUTHOR) alexandros.kokkosi@regeneron.com, Kokkosis, Alexandros^1,2 (AUTHOR) katia.karalis@gmail.com, Zambrowicz, Brian² (AUTHOR), Karalis, Katia^1,2 (AUTHOR), Pavlopoulos, Elias^1,2 (AUTHOR) jacky.chim@regeneron.com

Publikováno v: Pharmaceutics. Oct2024, Vol. 16 Issue 10, p1314. 25p.

Is there a possibility that P‐glycoprotein reduces reproductive toxicity in males but breast cancer resistance protein does not?

Autor: Yu, Zhiheng^1,2 (AUTHOR), Liu, Wei¹ (AUTHOR), Wang, Ziyu¹ (AUTHOR), Chen, Yidong^3,4 (AUTHOR), Yan, Jie^3,5 (AUTHOR) yanjiebjmu@bjmu.edu.cn, Benet, Leslie Z.⁶ (AUTHOR) leslie.benet@ucsf.edu, Zhai, Suodi¹ (AUTHOR) zhaisuodi@163.com

Publikováno v: CTS: Clinical & Translational Science. Oct2024, Vol. 17 Issue 10, p1-9. 9p.

Variability in P-Glycoprotein Inhibitory Potency (IC50) Using Various in Vitro Experimental Systems: Implications for Universal Digoxin Drug- Drug Interaction Risk Assessment Decision Criterias

Autor: Bentz, J., O'Connor, M.P., Bednarczyk, D., Coleman, J., Lee, C., Palm, J., Pak, Y.A., Perloff, E.S., Reyner, E., Balimane, P., Brännström, M., Chu, X., Funk, C., Guo, A., Hanna, I., Herédi-Szabó, K., Hillgren, K., Li, L., Hollnack-Pusch, E., Jamei, M., Lin, X., Mason, A.K., Neuhoff, S., Patel, A., Podila, L., Plise, E., Rajaraman, G., Salphati, L., Sands, E., Taub, M.E., Taur, J.-S., Weitz, D., Wortelboer, H.M., Xia, C.Q., Xiao, G., Yabut, J., Yamagata, T., Zhang, L., Ellens, H.

Publikováno v: Drug Metabolism and Disposition, 7, 41, 1347-1366

A P-glycoprotein (P-gp) IC50 working group was established with 23 participating pharmaceutical and contract research laboratories and one academic institution to assess interlaboratory variability in P-gp IC 50 determinations. Each laboratory follow

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=dedup_wf_001::d6daa80ed9b6fa01621a6cc185433f9e
http://resolver.tudelft.nl/uuid:de40ba57-f6e6-43f9-a972-add0da9ff716

Hepatobiliary Disposition of Atovaquone: A Case of Mechanistically Unusual Biliary Clearance.

Autor: Patel M; Mechanistic Safety and Disposition (M.P., M.J., C.W., H.E., J.W.P., M.J.Z.-G.) and Bioanalysis, Immunogenicity, and Biomarkers (C.J.S.), GlaxoSmithKline, King of Prussia, Pennsylvania; and Mechanistic Safety and Disposition, GlaxoSmithKline, Ware, United Kingdom (G.J.L.)., Johnson M; Mechanistic Safety and Disposition (M.P., M.J., C.W., H.E., J.W.P., M.J.Z.-G.) and Bioanalysis, Immunogenicity, and Biomarkers (C.J.S.), GlaxoSmithKline, King of Prussia, Pennsylvania; and Mechanistic Safety and Disposition, GlaxoSmithKline, Ware, United Kingdom (G.J.L.)., Sychterz CJ; Mechanistic Safety and Disposition (M.P., M.J., C.W., H.E., J.W.P., M.J.Z.-G.) and Bioanalysis, Immunogenicity, and Biomarkers (C.J.S.), GlaxoSmithKline, King of Prussia, Pennsylvania; and Mechanistic Safety and Disposition, GlaxoSmithKline, Ware, United Kingdom (G.J.L.)., Lewis GJ; Mechanistic Safety and Disposition (M.P., M.J., C.W., H.E., J.W.P., M.J.Z.-G.) and Bioanalysis, Immunogenicity, and Biomarkers (C.J.S.), GlaxoSmithKline, King of Prussia, Pennsylvania; and Mechanistic Safety and Disposition, GlaxoSmithKline, Ware, United Kingdom (G.J.L.)., Watson C; Mechanistic Safety and Disposition (M.P., M.J., C.W., H.E., J.W.P., M.J.Z.-G.) and Bioanalysis, Immunogenicity, and Biomarkers (C.J.S.), GlaxoSmithKline, King of Prussia, Pennsylvania; and Mechanistic Safety and Disposition, GlaxoSmithKline, Ware, United Kingdom (G.J.L.)., Ellens H; Mechanistic Safety and Disposition (M.P., M.J., C.W., H.E., J.W.P., M.J.Z.-G.) and Bioanalysis, Immunogenicity, and Biomarkers (C.J.S.), GlaxoSmithKline, King of Prussia, Pennsylvania; and Mechanistic Safety and Disposition, GlaxoSmithKline, Ware, United Kingdom (G.J.L.)., Polli JW; Mechanistic Safety and Disposition (M.P., M.J., C.W., H.E., J.W.P., M.J.Z.-G.) and Bioanalysis, Immunogenicity, and Biomarkers (C.J.S.), GlaxoSmithKline, King of Prussia, Pennsylvania; and Mechanistic Safety and Disposition, GlaxoSmithKline, Ware, United Kingdom (G.J.L.)., Zamek-Gliszczynski MJ; Mechanistic Safety and Disposition (M.P., M.J., C.W., H.E., J.W.P., M.J.Z.-G.) and Bioanalysis, Immunogenicity, and Biomarkers (C.J.S.), GlaxoSmithKline, King of Prussia, Pennsylvania; and Mechanistic Safety and Disposition, GlaxoSmithKline, Ware, United Kingdom (G.J.L.) maciej.x.zamek-gliszczynski@gsk.com.

Publikováno v: The Journal of pharmacology and experimental therapeutics [J Pharmacol Exp Ther] 2018 Jul; Vol. 366 (1), pp. 37-45. Date of Electronic Publication: 2018 Apr 13.

Derivation of a System-Independent K i for P-glycoprotein Mediated Digoxin Transport from System-Dependent IC 50 Data.

Autor: Chaudhry A; Departments of Biology (A.C., A.L., A.Y., M.O., J.B.) and Biodiversity, Ecology and Earth Sciences (M.O.), Drexel University, Philadelphia, Pennsylvania; Newcastle University, Institute for Cell and Molecular Biosciences, Newcastle upon Tyne, United Kingdom (G.C., C.B.); GlaxoSmithKline Pharmaceuticals, Drug Metabolism and Pharmacokinetics, King of Prussia, Pennsylvania (H.E.); and Ardea Biosciences Inc., Translational Sciences, San Diego, California (C.L.)., Chung G; Departments of Biology (A.C., A.L., A.Y., M.O., J.B.) and Biodiversity, Ecology and Earth Sciences (M.O.), Drexel University, Philadelphia, Pennsylvania; Newcastle University, Institute for Cell and Molecular Biosciences, Newcastle upon Tyne, United Kingdom (G.C., C.B.); GlaxoSmithKline Pharmaceuticals, Drug Metabolism and Pharmacokinetics, King of Prussia, Pennsylvania (H.E.); and Ardea Biosciences Inc., Translational Sciences, San Diego, California (C.L.)., Lynn A; Departments of Biology (A.C., A.L., A.Y., M.O., J.B.) and Biodiversity, Ecology and Earth Sciences (M.O.), Drexel University, Philadelphia, Pennsylvania; Newcastle University, Institute for Cell and Molecular Biosciences, Newcastle upon Tyne, United Kingdom (G.C., C.B.); GlaxoSmithKline Pharmaceuticals, Drug Metabolism and Pharmacokinetics, King of Prussia, Pennsylvania (H.E.); and Ardea Biosciences Inc., Translational Sciences, San Diego, California (C.L.)., Yalvigi A; Departments of Biology (A.C., A.L., A.Y., M.O., J.B.) and Biodiversity, Ecology and Earth Sciences (M.O.), Drexel University, Philadelphia, Pennsylvania; Newcastle University, Institute for Cell and Molecular Biosciences, Newcastle upon Tyne, United Kingdom (G.C., C.B.); GlaxoSmithKline Pharmaceuticals, Drug Metabolism and Pharmacokinetics, King of Prussia, Pennsylvania (H.E.); and Ardea Biosciences Inc., Translational Sciences, San Diego, California (C.L.)., Brown C; Departments of Biology (A.C., A.L., A.Y., M.O., J.B.) and Biodiversity, Ecology and Earth Sciences (M.O.), Drexel University, Philadelphia, Pennsylvania; Newcastle University, Institute for Cell and Molecular Biosciences, Newcastle upon Tyne, United Kingdom (G.C., C.B.); GlaxoSmithKline Pharmaceuticals, Drug Metabolism and Pharmacokinetics, King of Prussia, Pennsylvania (H.E.); and Ardea Biosciences Inc., Translational Sciences, San Diego, California (C.L.)., Ellens H; Departments of Biology (A.C., A.L., A.Y., M.O., J.B.) and Biodiversity, Ecology and Earth Sciences (M.O.), Drexel University, Philadelphia, Pennsylvania; Newcastle University, Institute for Cell and Molecular Biosciences, Newcastle upon Tyne, United Kingdom (G.C., C.B.); GlaxoSmithKline Pharmaceuticals, Drug Metabolism and Pharmacokinetics, King of Prussia, Pennsylvania (H.E.); and Ardea Biosciences Inc., Translational Sciences, San Diego, California (C.L.)., O'Connor M; Departments of Biology (A.C., A.L., A.Y., M.O., J.B.) and Biodiversity, Ecology and Earth Sciences (M.O.), Drexel University, Philadelphia, Pennsylvania; Newcastle University, Institute for Cell and Molecular Biosciences, Newcastle upon Tyne, United Kingdom (G.C., C.B.); GlaxoSmithKline Pharmaceuticals, Drug Metabolism and Pharmacokinetics, King of Prussia, Pennsylvania (H.E.); and Ardea Biosciences Inc., Translational Sciences, San Diego, California (C.L.)., Lee C; Departments of Biology (A.C., A.L., A.Y., M.O., J.B.) and Biodiversity, Ecology and Earth Sciences (M.O.), Drexel University, Philadelphia, Pennsylvania; Newcastle University, Institute for Cell and Molecular Biosciences, Newcastle upon Tyne, United Kingdom (G.C., C.B.); GlaxoSmithKline Pharmaceuticals, Drug Metabolism and Pharmacokinetics, King of Prussia, Pennsylvania (H.E.); and Ardea Biosciences Inc., Translational Sciences, San Diego, California (C.L.)., Bentz J; Departments of Biology (A.C., A.L., A.Y., M.O., J.B.) and Biodiversity, Ecology and Earth Sciences (M.O.), Drexel University, Philadelphia, Pennsylvania; Newcastle University, Institute for Cell and Molecular Biosciences, Newcastle upon Tyne, United Kingdom (G.C., C.B.); GlaxoSmithKline Pharmaceuticals, Drug Metabolism and Pharmacokinetics, King of Prussia, Pennsylvania (H.E.); and Ardea Biosciences Inc., Translational Sciences, San Diego, California (C.L.) bentzj@drexel.edu.

Publikováno v: Drug metabolism and disposition: the biological fate of chemicals [Drug Metab Dispos] 2018 Mar; Vol. 46 (3), pp. 279-290. Date of Electronic Publication: 2018 Jan 09.